Extracellular adenosine acts as a local modulator with a generally cytoprotective function in the body 1 . Its effects on tissue protection and repair fall into four categories: increasing the ratio of oxygen supply to demand; protecting against ischaemic damage by cell conditioning; triggering anti-inflammatory responses; and the promotion of angiogenesis 2 . There are four known subtypes of adenosine receptors (ARs) -referred to as A 1 , A 2A , A 2B and A 3 -each of which has a unique pharmacological profile, tissue distribution and effector coupling (FIG. 1) . All four subtypes are members of the superfamily of G-protein-coupled receptors (GPCRs), and are most closely related to the receptors for biogenic amines. Among the human ARs, the most similar are the A 1 and A 3 ARs (49% sequence similarity) and the A 2A and A 2B ARs (59% similarity).
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Extracellular adenosine levels are quite variable, depending on the tissue and the degree of stress experienced, and so the basal levels of stimulation of the four subtypes by the endogenous agonist vary enormously. The sources of adenosine are either release through an equilibrative transporter or as a result of cell damage 3 , or nucleotidase-mediated hydrolysis of extracellular adenine nucleotides 4 , which have their own signalling properties that are mediated by purinergic P2 receptors. Ectonucleotidases, of which the apyrase CD39 and the 5′-nucleotidase CD73 are prominent examples, are present on the extracellular surface of many tissues and are crucially involved in numerous important functions 4 . For example, in the brain, CD73 is known as a marker of astrocytes (but not neurons). These enzymes rapidly and effectively shift signalling by released adenine nucleotides and their products to signalling through ARs. Astrocytederived adenosine, acting on A 1 ARs, has a central role in the integration of synaptic activity by astrocytes that leads to widespread coordination of synaptic networks 5 . Adenosine itself is rapidly metabolized by adenosine kinase 6 and, to a lesser degree, adenosine deaminase to AMP and inosine, respectively, both of which are less active than adenosine at the ARs.
The development of potent and selective synthetic agonists and antagonists of ARs has been the subject of medicinal chemistry research for more than three decades. In addition, allosteric enhancers of agonist action could allow the effects of endogenous adenosine to be selectively magnified in an event-responsive and temporally specific manner, which might have therapeutic advantages compared with agonists 7 . AR action might also be modulated not only by direct-acting ligands, but by inhibition of the metabolism of extracellular adenosine 6 or its cellular uptake 3 . Although the basic science suggests that selective AR modulators have promise for numerous therapeutic applications, including cardiovascular, inflammatory and neurodegenerative diseases, in practice this goal has been elusive. One reason for this is the ubiquity of ARs and the possibility of side effects. In addition, species differences in the affinity of putatively selective ligands complicate preclinical testing in animal models. However, there has been a recent impetus towards novel clinical targets, in part as a result of the discovery of the A 3 AR subtype in the early 1990s and of the elucidation 
Bradycardiac effect
An arrhythmia typified by an abnormally slow heart rate.
of new roles for adenosine. In this review, we first present an overview of AR signalling, and summarize progress in the development of selective AR modulators. We then discuss the roles of the AR subtypes in disease, and preclinical and clinical results with AR modulators in various conditions.
AR signalling pathways and regulation
Classically, AR signalling is thought to occur through inhibition or stimulation of adenylyl cyclase (also known as adenylate cyclase), although it is now apparent that other pathways, such as phospholipase C (PLC), Ca 2+ and mitogen-activated protein kinases (MAPKs), are also relevant (FIG. 1) . Activation of the A 1 AR inhibits adenylyl cyclase activity through activation of pertussis toxin-sensitive G i proteins 8, 9 and results in increased activity of PLC 10, 11 . In cardiac muscle and neurons, A 1 ARs can activate pertussis toxin-sensitive K + channels, as well as K ATP channels, and inhibit Q-, P-and N-type Ca 2+ channels 1 . Coupling to K + channels in supraventricular tissue is responsible for the bradycardiac effect of adenosine on heart function 12 . In the heart, A 1 AR and A 2A AR agonistinduced preconditioning has been suggested to occur via modulation of p44/42 extracellular signal-regulated protein kinase (ERK) signalling 13 . Activation of the A 2A AR increases adenylyl cyclase activity. G s seems to be the major G-protein associated with A 2A ARs in the peripheral systems but not in the striatum, where A 2A AR density is the highest. It has been shown that striatal A 2A ARs mediate their effects predominantly through activation of G olf 14 , which is similar to G s and also couples to adenylyl cyclase. In rat tail artery, facilitation of noradrenaline release by activation of the A 2A AR triggers the PLC and adenylyl cyclase pathways 15 . Activation of the A 2A AR also induces formation of Figure 1 | Adenosine receptor signalling pathways. Activation of the A 1 and A 3 adenosine receptors (ARs) inhibits adenylyl cyclase activity through activation of pertussis toxin-sensitive G i proteins and results in increased activity of phospholipase C (PLC) via G βγ subunits. Activation of the A 2A and A 2B ARs increases adenylyl cyclase activity through activation of G s proteins. Activation of the A 2A AR to induce formation of inositol phosphates can occur under certain circumstances, possibly via the pertussis toxin-insensitive Gα15 and Gα16 proteins. A 2B AR-induced activation of PLC is through G q proteins. All four subtypes of ARs can couple to mitogen-activated protein kinase (MAPK), giving them a role in cell growth, survival, death and differentiation. CREB, cAMP response element binding protein; DAG, diacylglycerol; IP 3 , inositol 1,4,5-trisphosphate; PI3K, phosphatidylinositol 3-kinase; PIP 2 , phosphatidylinositol-4,5-bisphosphate; PK, protein kinase; PLD, phospholipase D; NF-κB, nuclear factor-κB. 
Mast cell
A type of leukocyte that has large secretory granules that contain histamine and various protein mediators.
inositol phosphates to raise intracellular calcium and activate protein kinase C in COS-7 cells via pertussis toxin-insensitive Gα15 and Gα16 proteins 16 , which have limited tissue distribution and interact with most GPCRs.
The A 2B AR is positively coupled to both adenylyl cyclase and PLC [17] [18] [19] [20] . Results indicate that the activation of PLC, through G q proteins, mediates many of the important functions of A 2B ARs 21, 22 . Activation of the A 2B AR by the non-selective agonist NECA increased inositol phosphate formation in human mast cell line HMC-1 (REF. 20 ), which is not sensitive to cholera or pertussis toxin but is antagonized by the slightly A 2B AR-selective antagonist enprofylline (3-propylxanthine) 20 . The arachidonic acid pathway was also recently demonstrated to be involved in A 2B AR activation 23 . The A 3 AR couples to classical second-messenger pathways such as inhibition of adenylyl cyclase 24 , stimulation of PLC 25 and calcium mobilization [26] [27] [28] [29] . In cardiac cells, A 3 AR agonists induce protection through the activation of K ATP channels 30 . RhoA-phospholipase D1 signalling has been demonstrated to mediate the antiischaemic effect of A 3 ARs
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. The WNT signalling pathway is involved in A 3 AR agonist-mediated suppression of melanoma cells 32 . In addition, like other ARs, the A 3 AR couples to MAPK, which could give it a role in cell growth, survival, death and differentiation 33, 34 . An A 3 AR agonist inhibits proliferation in A375 human melanoma cells via the phosphatidylinositol 3-kinase-protein kinase B-ERK1/2 pathway 35 .
Phosphorylation and subsequent desensitization of ARs have been studied for all four subtypes. The rapidity of the desensitization depends on the subtype, with the A 3 AR being more rapidly desensitized than the other subtypes 36 . GPCR kinase-mediated mechanisms are thought to have a crucial role in the rapid desensitization of A 2A and A 2B ARs 36 .
AR agonists and antagonists
The main approach for discovering AR agonists has been modification of adenosine itself, and the structure-activity relationships of adenosine at ARs have been extensively probed 37 . Most of the useful analogues are modified in the N 6 -or 2-position of the adenine moiety and in the 3′-, 4′-or 5′-position of the ribose moiety. Highly selective agonists of the various receptor subtypes (FIGS 2,3; TABLE 1) have been designed through both empirical approaches and a semi-rational approach based on molecular modelling 38, 39 . Similarly, the main approach for the discovery of AR antagonists (FIGS 4, 5) has been modification of xanthines such as caffeine and theophylline 40 . A modelling approach combining quantitative models of receptor and ligand has been demonstrated to accurately predict the potency of antagonists 41 . Molecular modelling of ARs using information from the crystal structure of the seventransmembrane protein rhodopsin, supported by mutagenesis studies, has also aided in understanding ligand recognition and provided insights into conformational dynamics 38, 42 . 
Photoisomerization
A conversion between structural isomers caused by light-induced excitation.
and selective antagonists for A 1 ARs have been derived by modification of the xanthines, including many 8-aryl and 8-cycloalkyl derivatives 40 . One such derivative is DPCPX, which is highly selective for rat A 1 AR compared with the A 2A AR (~500-fold) and less selective at the human A 1 ARs compared with human A 2A and A 2B ARs. Certain non-xanthine antagonists, such as the inverse agonist WRC-0571, derived from adenine, are A 1 AR selective, even compared with the A 2B AR 44 .
A 2A ARs. Substitution with small alkyl amide groups at the 5′-position of adenosine, as in the non-selective agonist NECA, provides increased potency at all the ARs, and this approach was also used to generate CGS21680, which is a moderately A 2A AR-selective agonist in rats (140-fold selectivity for the A 2A AR compared with the A 1 AR) but not humans 1, 43 . The selective agonist ATL-146e has much greater affinity for the A 2A AR than CGS21680 45 . Although most N 6 -substituted adenosine agonists are A 1 AR-or A 3 AR-selective, the agonist DPMA (diastereomeric pair) is more than 30-fold selective for the rat A 2A AR compared with the rat A 1 AR and A 3 AR subtypes, but has similar affinity at human A 1, A 2A and A 3 ARs 43, 46 . ZM241,385 and SCH 58261 are highly potent and selective A 2A AR antagonists 47, 48 , although ZM241,385 has been shown to bind with intermediate affinity at the human A 2B AR 46, 47 . The phenolic group of ZM241,385 can be radio-iodinated to provide an A 2A AR-selective radioligand 49 . . Selective antagonists have been reported; however, adenosine derivatives as selective A 2B AR agonists remain to be developed. Nearly all the known agonists are derivatives of adenosine. A notable exception is the development, on the basis of recent patents, of a series of pyridine-3,5-dicarbonitrile derivatives by IJzerman and colleagues 52 . These compounds act as AR agonists or partial agonists, with varying degrees of AR selectivity 52 , with LUF5835 being the most potent activator of the A 2B AR (EC 50 of 10 nM, FIG. 3a) .
Xanthines that have been developed as selective antagonists of the A 2B AR include MRS1754 and MRE 2029-F20, both of which have been prepared 
Paroxysmal supraventricular tachycardia
(PSVT). A regular, abnormally fast heart beat caused by rapid firing of electrical impulses from a focus above the AV (atrioventricular) node.
Atrial fibrillation
A condition in which disorganized electrical conduction in the atrial walls results in ineffective pumping of blood into the ventricle and an irregular heart rhythm.
Dromotropic
Refers to velocity of AV nodal conduction in the heart. as radioligands 53, 54 The 4′-thio modification of adenosine derivatives, explored for its effect on AR selectivity, has produced several highly potent and selective A 3 AR agonists, such as LJ568 (REF. 58 ). Conformational studies of the ribose moiety and its equivalents indicate that the ring oxygen is not required and that the North (N) ring conformation is preferred in binding to the A 3 AR. One means of locking the conformation of the ribose-like ring is through use of the bicyclo[3.1.0]hexane ring system, which assumes an (N)-envelope conformation 39, 42 . Highly selective A 3 AR agonists were recently reported in the series of (N)-methanocarba-5′-uronamide derivatives, including MRS3558, which has a K i value of 0.29 nM for the human A 3 AR 39 .
The search for A 3 AR antagonists began with the discouraging observation that xanthines -such as caffeine and theophylline, the classical antagonists of A 1 , A 2A and A 2B ARs -typically have low binding affinities for the A 3 AR 24 . Initial findings were reported for rat A 3 AR (before the report of the cloning of the human homologue) and many common xanthines have binding affinities of around 100 µM for this receptor. The cloning of the A 3 AR from other species facilitated further investigation of this receptor 59 . For sheep and human A 3 ARs, xanthines have intermediate affinity (typically 100 nM for 8-phenylxanthine analogues). There is a marked species dependence of antagonist affinity at the A 3 AR, with human affinity typically greatly exceeding that at the rat receptor for xanthine and other non-purine A 3 AR antagonists 24, 60 . Therefore, the search for A 3 AR antagonists turned towards more novel heterocyclic systems 56 . The screening of diverse chemical libraries resulted in the identification of new high-affinity hits for the human A 3 AR, including dihydropyridines, flavonoids, pyridines, thiazoles and others, which were then optimized, typically by substitution of aromatic rings 40, 41, 56 . The dihydropyridine derivative MRS1334 (not active at L-type calcium channels) and the pyridylquinazoline VUF5574 (not selective in rat) are both relatively potent A 3 AR antagonists, with K i values of 2.7 and 4.0 nM, respectively, at the human subtype. The pyridine derivative MRS1523 is a selective A 3 AR antagonist in both rat and human. PSB-11, which is a selective antagonist for human A 3 ARs, was tritiated for characterization of this receptor 61 . Numerous adenine derivatives have been studied as selective antagonists for A 1 or A 2A ARs, and the adenine derivative MRS3777 was recently reported to be highly selective for the human A 3 AR 62 .
An alternative approach to designing A 3 AR antagonists is to start with high-affinity adenosine derivatives and truncate the molecule in stages to remove the capacity to activate the receptor without compromising high-affinity binding. An initial attempt to find adenine derivatives, such as 9-alkyl-N 6 -iodobenzyladenines, that displayed these characteristics was unsuccessful 56 . A more successful approach either added substituents to adenosine derivatives or rigidified the nucleosides, to reduce their intrinsic efficacy 42 . With more systematic studies of structure-efficacy relationships on substitution of adenosine at the N 6 , ribose and C2 adenine positions, it became apparent that the efficacy at A 3 ARs is more easily diminished by structural modification than it is at the other AR subtypes 42, 43 . In some cases, N 6 -substitution of adenosine 5′-OH derivatives with large groups (for example, substituted benzyl groups or large cycloalkyl rings) reduced the maximal efficacy, leading to decreased efficacy at the A 3 AR. For example, CCPA and DPMA, which are full agonists at A 1 and A 2A ARs, respectively, are A 3 AR antagonists. This structural insight was used advantageously to obtain the conformationally constrained nucleoside MRS1292, which proved to be a selective A 3 AR antagonist in both rat and human 42, 60 .
ARs as targets in cardiovascular disease
Arrhythmia. A 1 AR activation has a number of effects in the cardiovascular system, including a reduction in heart rate and atrial contractility, and the attenuation of the stimulatory actions of catecholamines on the heart 63, 64 . Activation of the A 1 AR by intravenous infusion of adenosine (Adenocard; Astellas Pharma) is used to restore normal heart rhythm in patients with paroxysmal supraventricular tachycardia (PSVT). However, for more long-term indications, selective A 1 AR modulators are needed to avoid side effects related to other AR subtypes such as hypotension.
Selodenoson (DTI0009, GR 56072, RG 14202; Aderis Pharmaceuticals) is a potent and selective A 1 AR agonist with the potential to control heart rate without lowering blood pressure 65 . It has been tested in Phase II clinical trials for its capacity to slow heart rate in atrial fibrillation, although it has been reported to have renal toxicity. Tecadenoson (CVT-510) is a potent A 1 AR agonist with a dose-dependent negative dromotropic effect on the AV node 66 . In patient trials (now Phase III), it terminated PSVT without the side effects associated with other AR subtypes, such as hypotensive effects. CVT-2759 is a partial agonist of the A 1 AR, which in guinea pig heart seems to be useful in slowing down AV nodal conduction and thereby ventricular rate without causing AV block, bradycardia, atrial arrhythmias or vasodilation 63 . SDZ WAG 994 was extensively characterized in clinically relevant models 67 and has been in Phase I clinical trials for the potential treatment of PSVT. However, development of this agent was discontinued in 1999.
Ischaemia. Adenosine is released in large amounts during myocardial ischaemia, resulting in effective preconditioning in cardiomyocytes through the activation of A 1 and A 3 ARs [29] [30] [31] 68 . Administration of a synthetic AR agonist to activate either or both of these receptors might therefore be beneficial to the survival of the ischaemic heart. Ischaemic cardiac preconditioning by the A 1 AR involves a series of intracellular events that begin with the activation of the receptor and end at the sensitive K + -ATP channels of the mitochondria. Most of the pharmacological data indicate that A 1 ARs have an important role in protection of the heart and brain from ischaemia-reperfusion injury 1 . The A 1 AR-agonist-induced decreases in blood pressure and heart rate are mediated by the peripheral A 1 ARs, with little or no contribution of central A 1 ARs, which is consistent with the observation that typical agonists cross the blood-brain barrier to only a small degree 69 . An important role of the A 1 AR in protection of the murine heart by remote, delayed adaptation has been demonstrated 70 . Cardiac overexpression of A 1 ARs in mouse heart results in substantial protection from ischaemiareperfusion injury [71] [72] [73] . Hearts isolated from transgenic animals with overexpression of A 1 ARs have a lower basal rate than those of control mice 71 . Cardioprotection in wild-type hearts and hearts overexpressing A 1 ARs was mediated by mitochondrial K + -ATP channel activation 74 . A 1 AR overexpression also improves myocardial tolerance to anoxia reoxygenation, in addition to protecting hearts from ischaemia-reperfusion injury 75 . The cardiovascular effects of the A 1 AR agonist CPA also convey protection against Sarin poisoning 76 . It is well documented that adenosine can protect tissues against hypoxia or ischaemia through A 1 ARs. In the A 1 AR-knockout mouse heart, baseline contractile function and heart rate were unaltered, but intrinsic myocardial resistance to ischaemia was limited 77 . In addition, non-selective receptor agonism induced by 2-chloroadenosine was cardioprotective in A 1 AR-knockout (albeit to a lesser extent) and wild-type hearts, indicating additional protective mechanisms through other AR subtypes.
Various lines of evidence indicate that the A 3 AR has a role in protecting the heart 68, 78 . Overexpression of A 3 ARs decreases heart rate, preserves energetics and protects ischaemic hearts 79 , and low-level expression of A 3 ARs in the heart provides effective protection against ischaemic injury without detectable adverse effects, although higher levels of A 3 AR expression lead to the development of a dilated cardiomyopathy 80 . Paradoxically, global deletion of the A 3 AR in mice also confers resistance to myocardial ischaemic injury and does not prevent early preconditioning 81 . In an isovolumic Langendorff perfusion model, A 3 AR-knockout mice also had improved functional recovery and tissue viability during reperfusion after ischaemia when compared with control mice 78 . In one study, administration of an A 3 AR agonist in wild-type and A 3 AR-knockout mice showed similar cardioprotective effects: post-ischaemic recovery was enhanced in A 3 AR-knockout mice 82 , implying action of the agonist at a non-A 3 AR, probably the A 2A AR. It has been demonstrated that, in addition to the role of A 1 and A 3 AR agonists, the A 2A AR activation is protective against ischaemia-reperfusion injury in mice, which has been proposed to be mainly due to its actions on lymphocytes 83 . An A 3 AR-mediated direct cardioprotective effect has been evident 31 . However, the A 3 AR expression level is low in cardiomyocytes. So, an indirect protective effect has also been proposed, for example, through modulation of the function of mast cells and neutrophils, in which A 3 ARs are abundant. A 3 AR signalling in rodent mast cells may be detrimental to the myocardium because of a pro-inflammatory mechanism, but this response might only be observed in rodents (that is, mouse A 3 AR-knockout experiments) because mast cell degranulation seems to be A 2B AR-dependent in humans and dogs 1 . This could at least in part explain the paradoxical effects observed in various experiments 75, 81, 82 . Another explanation of the paradoxical effect could be the numerous compensatory mechanisms observed in receptor-knockout mice 84 . Some studies have shown that activation of either A 1 or A 3 ARs could trigger protection of function in preconditioned rat hearts, although maximal preconditioning requires activation of both A 1 and A 3 ARs 85, 86 . The selective agonists CCPA and Cl-IB-MECA have been used to discern two separate A 1 and A 3 AR-mediated pathways leading to cardioprotection, either as early or late preconditioning or during prolonged ischaemia. Unlike the case of A 1 AR-mediated cardioprotection, A 3 AR-mediated cardioprotection is achieved in vivo in the absence of haemodynamic side effects, such as hypotensive effects, and could therefore be therapeutically more promising 68 . Stimulation of A 3 ARs could also be advantageous over A 1 AR activation because it may be less likely to induce bradycardia 85 . The A 3 AR agonist CP608039 is in development for use in perioperative cardioprotection 78 , and the A 3 AR agonist Cl-IB-MECA protects rat cardiac myocytes from the toxicity induced by the cancer chemotherapeutic agent doxorubicin 87 .
Vasodilation. The A 2A AR is involved in vasodilation in the aorta and coronary artery 1 . It was suggested that the tachycardic effect of A 2A AR activation is mediated by centrally located receptors, whereas its hypotensive effect is mediated by the peripheral A 2A AR 69 . In the late 1960s and 1970s, metabolically stable AR agonists were tested clinically as antihypertensives, and this was an intended use of the A 2A AR agonist CGS21680; however, its clinical path was curtailed following canine haemodynamic studies due to in vivo non-selectivity related to spare receptors. In platelets, an A 2A AR agonist was shown to inhibit aggregation by increasing intracellular cAMP levels, suggesting that adenosine agonists might have utility as antithrombotic agents 88 . Recently, there has been an effort to further improve subtype-selectivity of A 2A AR agonists for novel therapeutic applications, including imaging. Adenosine, under the name Adenoscan (Astellas Pharma), is used in myocardial stress imaging to evaluate coronary artery disease by achieving vasodilation in patients unable to exercise adequately. Regadenoson (CVT-3146), a potent and selective A 2A AR agonist, is being evaluated in Phase III studies for the same purpose
Discriminative stimulus
In instrumental conditioning, the external stimulus that signals a particular relationship between the instrumental response and the reinforcer.
during myocardial perfusion imaging 89 . The selective A 2A AR agonist binodenoson (WRC-0470) has entered Phase III clinical trials and seems to be well tolerated as a short-lived coronary vasodilator and acts as an adjunct to radiotracers in imaging 90 . ATL-146e, the most selective of these A 2A AR agonists, has also entered Phase III clinical trials for coronary imaging.
Activation of the A 2B AR induces vasodilation in some vascular beds 91, 92 , such as the main pulmonary artery of guinea pigs, and induces human chorionic vasoconstriction and signals through the arachidonic acid cascade 23 . The A 2B AR is selectively upregulated by hypoxia, and A 2B AR antagonists effectively neutralize ATP-elicited reduction in post-hypoxic endothelial permeability 93 . Inhibition of mitosis of rat aortic smooth-muscle cells has been achieved through selective A 2B AR activation 94 . The A 2B ARs are also important for adenosine-mediated inhibition of cardiac fibroblast functions 95 and the stimulation of nitric oxide production during Na + -linked glucose or glutamine absorption 96 . Activation of the A 2B AR promotes angiogenesis by increasing the release of angiogenic factors 2, 97 . Cutaneous vasopermeability, which is associated with activation and subsequent degranulation of mast cells, is completely lost in mice lacking functional A 3 ARs 98 . One of the well-known actions of adenosine is to dilate vascular beds. Interestingly, the concentration of cAMP is higher in the aortae of A 3 AR-deficient mice, with no significant change in the amount of A 1 or A 2A ARs, than it is in control mice. The hypotensive effect observed after intravenous adenosine injection in mice lacking the A 3 AR was significantly larger than in control mice 99 . Genetic deletion of the A 3 AR or antagonism of the A 3 AR augmented coronary flow induced either by adenosine or by the A 2A AR agonist CGS21680 (REF. 100 ). However, A 3 ARs do not regulate atherogenesis; the development of atherosclerosis and response to injury of the femoral artery were similar to those in wild-type mice 101 . It has been clearly demonstrated that both agonist-and antagonist-binding profiles for the murine and human A 3 ARs are different. The marked species difference, together with the paradoxical protection in A 3 AR-knockout hearts despite A 3 AR-mediated protection in wild-type hearts, could reflect limitations of gene-knockout studies, and the A 3 AR-knockout data from mice should be interpreted with caution. Also, it should be noted that the selective ligands currently available are only relatively selective for a certain AR subtype. At relatively high concentrations, these ligands may also activate or block other AR subtypes. As such, cautious and thoughtful interpretation of pharmacological data is necessary.
ARs as targets in nervous system disorders
Observations of the effects of caffeine -a classical AR antagonist -on the nervous system, such as enhancement of awareness and learning, have encouraged the investigation of selective AR antagonists in the nervous system. Indeed, the A 1 AR was recently shown to be involved in the discriminative-stimulus effects of caffeine 102 . However, it is the A 2A AR, which was the first AR to be genetically deleted 103 , that is the primary mediator of the behavioural stimulatory effects of caffeine [103] [104] [105] , and this receptor also has an important role in sleep regulation (see below) 106 . Although high concentrations of caffeine can also block phosphodiesterases, which can have numerous behavioural consequences 104 , most of the varied stimulant and other behavioural effects of caffeine are thought to result from antagonism of ARs in the nervous system. This suggests that modulation of ARs may provide therapeutic targets in nervous system disorders, in such diverse conditions as dementia and other neurodegenerative diseases, hyperactivity, anxiety, schizophrenia and sleep disorders.
Dementia and anxiety disorders. Recently, the novel A 1 AR-selective antagonist FR194921 (which did not show any species differences in its high A 1 AR affinity) was reported to have potential in the treatment of dementia and anxiety disorders 107 . FR194921 was orally active and centrally available, ameliorated scopolamineinduced memory deficits, and also showed anxiolytic effects in the elevated plus maze test, without influencing general behaviour or having antidepressant activity 107 .
Pain. Adenosine exerts multiple influences on pain transmission at peripheral and spinal sites. At peripheral nerve terminals in rodents, A 1 AR activation produces antinociception by decreasing cAMP levels in the sensory nerve terminal 108 . Mice lacking functional A 1 AR show signs of increased anxiety and hyperalgesia, and the analgesic effects of adenosine observed in wild-type mice are lost 109 . A recent study using A 1 AR-knockout mice suggested that A 1 ARs might be more important in chronic pain than in acute pain 110 . In humans, infusion of adenosine in the spinal cord was effective in decreasing post-operative pain 111 . The A 1 AR agonist GR79236 administered in cats had a dose-dependent inhibitory effect on trigeminovascular nociceptive transmission, which is otherwise associated with the initiation of local increases in blood flow and enhanced protein permeability -that is, factors that contribute to vascular headaches 112 . A 1 AR activation leads to neuronal inhibition without concomitant vasoconstriction, indicating that this might be an effective treatment of migraine and cluster headache. Another A 1 AR agonist, GW-493838, was evaluated in Phase II clinical trials for the treatment of pain and migraine, and was found to inhibit electrically induced nociceptionspecific blink reflex responses 113 . The A 1 AR-selective allosteric enhancer T-62 (FIG. 6) was also shown to reduce hypersensitivity in carageenin-inflamed rats by a central mechanism 114 . T-62 has entered Phase I clinical trials as a treatment for neuropathic pain. . In SH-SY5Y human neuroblastoma cells, A 2A AR-D 2 R heteromeric complexes undergo co-aggregation and co-internalization as a result of long-term exposure to A 2A AR or D 2 R agonists 116 . Independent action of the A 2A AR and D 2 R has also been proposed in A 2A AR-knockout studies 117 . In D 2 R-knockout mice, A 2A AR agonists and antagonists produce behavioural and cellular functions that are similar to those of their wild-type counterparts, suggesting a D 2 R-independent mechanism 118, 119 . 123, 124 , and other A 2A AR antagonists, such as V2006 (a derivative of the antimalarial drug mefloquine), are in development [124] [125] [126] . V2006, which is beginning Phase II clinical trials, is well tolerated in high doses, and its pharmacokinetic properties suggest that it should be suitable for daily dosing. In the brain, adenosine released under stress conditions counteracts the release and damaging effects of excitatory neurotransmitters, such as glutamate, by activation of the A 1 AR. ADAC, an A 1 AR agonist, was potent in cerebroprotection in a model of global ischaemia in gerbils 134 . The A 1 AR agonist NNC-21-0136 was neuroprotective in both global and focal rodent ischaemia models and had diminished cardiovascular effects in rats compared with reference A 1 AR agonists, such as CPA 135 . However, it was recently shown that deletion of the gene that encodes the A 1 AR does not alter neuronal damage that occurs after ischaemia in vivo or in vitro 136 , although A 1 ARs have been shown to be relevant to hypoxia protection in newborn mice 137 . Glial cells express all the ARs, and A 2A AR activation was found to promote myelination in Schwann cells, suggesting that a selective agonist could be useful in treating demyelinating diseases such as multiple sclerosis 138 . Although A 3 AR expression levels are low in all regions of the brain [139] [140] [141] , an A 3 AR agonist (IB-MECA) depresses locomotor activity in mice 142 , suggesting a role for the A 3 AR in depression of motor activity. Chronic administration of the A 3 AR agonist IB-MECA was highly effective in a gerbil model of cerebroprotection against global ischaemia 143 , and deletion of the A 3 AR has a detrimental effect in a model of mild hypoxia, suggesting the possibility of using A 3 AR agonists to treat cerebral ischaemia.
Ischaemia and neuroprotection.
Sleep. Adenosine has been found to be an important endogenous sleep-promoting substance 144, 145 . It mediates the somnogenic effects of prior wakefulness, and also seems to have an important role in the regulation of the duration and depth of sleep after wakefulness 144 . Pharmacological data suggest that A 1 ARs are involved in the regulation of sleep 145 , but lack of A 1 ARs does not prevent the homeostatic regulation of sleep 146 . Therefore, it is possible that although the A 1 AR is an important factor for sleep regulation in normal animals, other factors, such as the A 2A AR, could compensate for the role of A 1 AR when it is deleted. Indeed, it was recently shown that the A 2A AR has a key role in adenosine-mediated sleep-promoting effects 147 . It has been suggested that the cholinergic basal forebrain is an essential area for mediating the sleep-inducing effects of adenosine by inhibition of wakefulness-promoting neurons via the A 1 AR, and the A 2A AR in the subarachnoid space below the rostral forebrain could have a role in the prostaglandin D 2 Rmediated somnogenic effects of adenosine 148 . The arousal effect of caffeine was recently shown to be dependent on the A 2A AR 105 . However, the locomotor stimulatory effect of high doses of caffeine is not the result of the blockade of either the A 1 AR or the A 2A AR, and an effect that is independent of AR activity is probable 104 . Although the concept of using AR agonists as modulators for sleep disorders is intriguing, in practice this would be dependent on brain-selective receptor activation.
Other potential applications. Adenosine is important in mediating at least some of the neuronal responses to ethanol 149, 150 . Ethanol increases brain levels of adenosine by inhibiting adenosine reuptake, which activates A 2A ARs and thereby raises cAMP concentrations. The resulting activation of protein kinase A leads to activation of cAMP response element (CRE)-mediated gene expression. Alcohol and adenosine therefore interact synergistically with the activation of D 2 Rs in median spiny neurons of the striatum/nucleus accumbens, unlike the otherwise antagonistic relationship between dopamine and adenosine. This is thought to involve the G-protein β,γ dimers, the inhibition of which reduces voluntary alcohol consumption. Therefore, drugs that antagonize the synergism of A 2A AR and D 2 R effects might be useful in controlling alcohol abuse.
There has also been recent progress in the imaging of ARs in the brain. An 18 F analogue of DPCPX has been developed as a positron-emission tomographic imaging agent 151 . The highly potent and selective A 2A AR antagonist SCH442416 in 11 C-labelled form has been established as an in vivo receptor-imaging agent in the rat and primate brain, which may eventually strengthen the link between the A 2A AR and disease states, as well as aid in identifying those patients that are likely to benefit from adenosine-related therapeutics 152 . Finally, blockade of A 2A AR has a clear antidepressant effect 153 , suggesting that selective A 2A AR antagonists could be pursued as antidepressant drugs. A 1 AR activation has also been a target in the development of antiepileptic therapy 6 , and an inhibitor of adenosine kinase was shown to inhibit seizure activity in animals 6 .
ARs as targets in renal system disorders Activation of A 1 AR protected against ischaemiareperfusion-induced kidney injury 154 . Pretreatment of C57BL/6 mice with an A 1 AR antagonist caused a significant deterioration in renal function 154 . In addition, A 1 AR expression protects renal proximal tubular epithelial cells against cisplatin-mediated apoptosis 155 . Mice lacking A 1 ARs showed a completely blocked renal glomerular filtration rate by a tubuloglomerular feedback mechanism 156, 157 , and A 1 AR-knockout mice had increased renal injury after ischaemia and reperfusion 158 . Therefore, the kidney protective effect of A 1 AR agonists has been evident, which provides the basis for their future development as drugs for the treatment of renal failure.
Unlike A 1 AR agonists, A 1 AR antagonists are effective diuretic agents that are useful in treating fluid-retention disorders, including congestive heart failure, although antagonism of A 1 ARs is potentially a concern when using these agents in patients with ischaemic heart and kidney injury. An A 1 AR antagonist, BG9719 (CVT-124), was in Phase II clinical trials (now discontinued) for the treatment of acute renal disorders in patients with congestive heart failure 159, 160 . However, BG9719 contains an epoxide group, which is potentially chemically reactive. However, a nonepoxide-containing antagonist in the same series, BG9928, improves renal function and congestive heart failure without exacerbating cardiac injury 161 . BG9928, now in Phase II clinical trials, was found to improve sodium excretion in heart failure patients.
A 2A AR agonist-mediated cellular protection is particularly evident in peripheral tissues, including the kidney 2 . The A 2A AR in bone marrow-derived cells is also responsible for protection against ischaemic injury in the kidney 162 . A recently developed A 2A AR agonist, ATL-146e, was shown to protect against ischaemic renal injury 163 , and the mixed A 1 /A 2A AR agonist AMP579 was initially tested in patients with end-stage renal insufficiency; however, further clinical testing of the compound is impossible due to its inhibition of HERG channels 164 . The expression of the A 2B AR in the kidney 165 and the presence of endogenous A 2B ARs in the HEK-293 cell line 166 suggested a potential role in the kidney for this subtype, which is known to regulate cell growth and proliferation 167 . Finally, mice lacking the A 3 AR or wild-type mice in which the A 3 AR was blocked pharmacologically had significant renal protection 168 , suggesting that A 3 AR antagonists might have general renal-protective properties. Recent evidence suggested that both A 1 AR agonists and A 3 AR antagonists protect the kidney. Ligands possessing dual acting and opposite properties at these AR subtypes could therefore be effective therapeutic agents for renal protection.
ARs as targets in pulmonary disorders
A protective role for the A 1 AR in adenosine-dependent pulmonary injury has been proposed 169 . Genetic removal of the A 1 AR from adenosine deaminase-deficient mice caused enhanced pulmonary inflammation along with increased mucus metaplasia and alveolar destruction. The expression of T H 2 cytokines interleukin-4 (IL-4) and IL-13 in the lungs, as well as chemokines and matrix metalloproteinases, was upregulated. These findings imply that A 1 AR agonists have potential for the therapeutic treatment of pulmonary injury.
In the asthmatic lung, adenosine acts as an irritant and bronchoconstrictor, and so a synthetic AR antagonist, perhaps selective for the A 2B AR, could have therapeutic potential in asthma treatment 170 . In mouse mast cells, A 3 AR activation has been shown to induce mast-cell degranulation 171 . It has been suggested that this effect is mediated by the A 2B AR in human and canine mast cells [172] [173] [174] . A bioavailable thiazole derivative that acts as a mixed antagonist at A 2B and A 3 ARs has been proposed to be a candidate therapeutic agent for the treatment of asthma 175 ; however, this has not been tested in animal models. In addition, the bronchodilating, anti-asthmatic effects of theophylline and other xanthines might involve A 2B AR blockade, although the evidence for this is controversial due to the lack of an adequate animal model. The lack of A 2B AR-selective agonists and, until recently, A 2B AR-knockout mice have hampered further clarification of the functional significance of this receptor.
Activation of the A 2A AR by CGS21680 produces broad-spectrum anti-inflammatory activity in a model of allergic asthma in the Brown Norway rat, suggesting that A 2A AR agonists could be useful alternatives to glucocorticosteroids in the treatment of asthma 176 . GW328267, an A 2A AR agonist designed for intranasal administration, was also evaluated in Phase II clinical trials for upper respiratory inflammatory disease, chronic obstructive pulmonary disease and asthma; however, the results at the dose used were negative and the compound has been withdrawn from clinical testing 177 . In preclinical testing, the A 3 AR agonist IB-MECA was shown to protect against lung injury and apoptosis in cats after reperfusion 178 , and this protection was antagonized by MRS1191, a dihydropyridine that is a selective A 3 AR antagonist 56 .
As described earlier, prominent species differences in the structure and function of ARs, especially the A 3 AR, have been observed. For example, human and rat A 3 ARs only share 72% overall identity at the amino-acid level; mast-cell degranulation is induced by the A 2B AR in dogs and humans, but by the A 3 AR in mice. It is therefore plausible that some of the functions observed with one animal model might not be obtained in other animal models and in humans. Cross-species testing systems are necessary to validate the receptor function or effects of agonists and antagonists.
ARs as targets in inflammatory disorders
Adenosine-mediated activation of the A 2A AR, which is found in almost all immune cells, including lymphocytes, monocytes, macrophages and dendritic cells 179 , seems to attenuate inflammation and reperfusion injury in a variety of tissues. Through A 2A AR activation, adenosine can inhibit T-cell activation, proliferation and production of inflammatory cytokines while enhancing the production of anti-inflammatory cytokines. Activation of the A 2A AR in T H and cytotoxic T lymphocytes directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo 180 . In murine CD4 + T cells, the A 2A AR agonists ATL-146e and ATL-313 were shown to reduce T cell-receptor (TCR)-mediated production of interferon-γ (IFNγ). Rapid-induction TCR signalling of the mRNA for the A 2A AR suggests that this is a mechanism for limiting T-cell activation and secondary macrophage activation in inflamed tissues 181 . Ohta and Sitkovsky 182 reported that A 2A ARs are crucially involved in the limitation and termination of prolonged inflammation. Knockout of the A 2A AR in mice showed that no other mechanism for inflammation could compensate fully for the loss of the A 2A AR (which has been referred to as a brake for inflammation 183 ) on immune cells. Interestingly, in knockout mouse models, the A 2A AR together with the A 3 AR mediated the antiinflammatory effect of methotrexate, which is used as a treatment of arthritis 184 . ATL-146e, a selective agonist of the A 2A AR, profoundly protects mouse liver from reperfusion injury, and the protection is blocked by the A 2A AR antagonist ZM241385. In mice lacking the A 2A AR, protection by ATL-146e is lost and ischaemic injury of short duration is exacerbated, which contrasts with the results obtained in wild-type mice, suggesting a protective role for endogenous adenosine 185 . The A 2A AR agonist ATL-146e is also of interest for the treatment of sepsis 186 , inflammatory bowel disease 187 and for inclusion in drug-eluting stents to prevent restenosis after angioplasty. Selective activation of the A 2A AR has also been shown to reduce skin pressure, ulcer formation and inflammation 188 , and wound healing is accelerated 189 . The A 3 AR has been implicated in mediating allergic responses in mice; it facilitates the release of allergic mediators, such as histamine, in mast cells 190 . Systemic infusion of IB-MECA causes scratching in mice that is prevented by co-administration of histamine antagonists 142 . The potentiation by Cl-IB-MECA of antigendependent degranulation of mast cells, as measured by hexosaminidase release, was lost in mice lacking A 3 ARs 171 . Attenuation of lipopolysaccharide-induced tumour-necrosis factor-α (TNFα) production was lower in mice lacking the A 3 AR than in control mice 171 . Finally, adenosine has been implicated in arthritis treatment, and the possibility of administration of A 2A AR agonists for this purpose remains open 191 . The A 3 AR agonist IB-MECA also showed beneficial effects in early human trials 192 .
ARs as targets for endocrine disorders A 1 AR agonists are under consideration as therapeutic candidates for obesity-related insulin resistance and type 2 diabetes 193 . In mice overexpressing the A 1 AR in adipose tissue, lower concentrations of plasma free fatty acids were observed than in litter-matched controls, and the transgenic mice did not develop insulin resistance. This supports a significant physiological role for adipocyte A 1 AR in the control of lipolysis. GR79236 has been tested in humans for adjuvant therapy in insulin resistance (type 2 diabetes). This A 1 AR agonist ameliorates the hypertriglyceridaemia induced by fructose feeding, and the reduction in fatty acid levels is associated with secondary improvements in glucose tolerance.
A 2B AR antagonists are also under consideration for diabetes treatment. A 2-alkynyl-8-aryl-9-methyladenine derivative developed by Eisai showed hypoglycaemic activity in an animal model of type 2 diabetes, suggesting that adenosine agonist-induced glucose production in rat hepatocytes is mediated through the A 2B AR 194 . The A 2A AR agonist MRE-0094 is in Phase I clinical trials as a treatment for chronic diabetic neuropathic foot ulcers due to the anti-inflammatory and wound healing effects of A 2A AR agonists. 
Agonists Antagonists
ARs as targets in cancer A 3 AR agonists can induce or attenuate apoptosis depending on the range of agonist concentrations used, which might have important implications for their therapeutic use in disorders in which the aim is to either attenuate apoptosis, such as arthritis (see above), or induce it, as in cancer. In human eosinophils and human promyelocytic HL-60 cells 195, 196 the A 3 AR agonist Cl-IB-MECA seems to induce apoptosis at relatively high concentrations (>10 µM), but in RBL-2H3 cells, a lower concentration (1 µM) of the A 3 AR agonist IB-MECA block apoptosis that is induced by ultraviolet irradiation 197 . A role for the A 3 AR in mediating control of the cell cycle has been reported 198 . Activation of the A 3 AR by adenosine triggers a cell survival response; by contrast, activation of A 2A ARs induces an apoptotic signalling pathway that involves protein kinase C and MAPKs 199 . Overexpression of the A 3 AR in transgenic mice resulted in embryonic lethality 141 , suggesting the possible use of selective A 3 AR agonists in anticancer therapy.
A 3 AR activation has been implicated in inhibition of tumour growth both in vitro and in vivo 200 , and IB-MECA is in clinical trials for colon carcinoma. However, the novel anticancer effect discovered by Fishman and colleagues is caused by a cytostatic effect on tumours related to the WNT pathway 32 , rather than Figure 7 | Novel disease targets for selective adenosine receptor ligands. Most promising prospects exist for treatment of arrhythmias, ischaemia of the heart and brain, pain, neurodegenerative diseases, sleep disorders, inflammation, diabetes, renal failure, cancer and glaucoma, and in cardiovascular imaging. High and intermediate levels of A 1 adenosine receptor (AR) expression were found in the brain, heart, adipose tissue, stomach, vas deferens, testis, spleen, kidney, aorta, liver, eye and bladder
140
. The A 2A AR is highly expressed in the striatum, nucleus accumbens and olfactory tubercle 140 . High and intermediate expression levels were also found in immune cells, heart, lung and blood vessels. The A 2B AR was generally expressed at low levels in almost all tissues 140 . Rat testis has particularly high concentrations of A 3 AR mRNA, with moderate levels in lung. The highest levels of human A 3 AR mRNA have been found in lung and liver. A 3 ARs have been detected in various tissues including testis, lung, kidney, placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, aorta, proximal colon and eyes.
Box 1 | Neoceptors
Because of the widespread distribution of native adenosine receptors (ARs), their activation is inherently nonselective. To address this issue, efforts have been made to reengineer ARs into 'neoceptors' that can recognize uniquely modified nucleosides that are inactive at the native ARs 38, 205, 206 . This neoceptor strategy, which is intended for eventual use in organ-targeted gene therapy, is made possible by modelling of the putative ligand-binding site of a G-protein-coupled receptor, leading to identification of sites for mutagenesis, and incorporation of a complementary functional group in a synthetic agonist (neoligand). A novel electrostatic or H-bonding pair formed between the neoceptor and neoligand allows receptor activation that is orthogonal with respect to the native species 209 . So far, neoceptors have been developed for A 2A and A 3 ARs.
by induction of apoptosis. Recently, it was shown that the A 3 AR is more highly expressed in tumour than in normal cells, which may justify A 3 AR as a potential target for tumour growth inhibition 201 . In human breast cancer cell lines, IB-MECA downregulated the oestrogen receptor and completely inhibited cell growth 202 .
ARs as targets in visual disorders
The A 3 AR-knockout mouse had significantly lower intraocular pressure, suggesting that A 3 AR antagonists have potential in the treatment of glaucoma 203 . Most reported A 3 AR antagonists are selective only at the human A 3 AR, and so are not suitable for use in rodent models, but the selective A 3 AR antagonist OT-7999 reduced intraocular pressure in the monkey 204 . Encouragingly, the cross-species A 3 AR antagonist MRS1292 was recently found to reduce mouse intraocular pressure and also inhibited adenosine-triggered human non-pigmented ciliary epithelial cell fluid release 60 .
Conclusions
The medicinal chemistry of ARs is well developed, and selective agonists and antagonists have been generated for most of the receptor subtypes. In addition to the potential of directly acting orthosteric ligands, allosteric modulation of ARs is a promising approach. The application of genetic therapy with neoceptors could also potentially achieve organ or tissue selectivity in the future
.
With suitable pharmacological probes and the availability of knockout mice for three of the four subtypes, the basic science of ARs has progressed to the identification of novel therapeutic targets (FIG. 7) . It is hoped that new agents in development will avoid the undesirable side effects that have impeded the clinical development of AR ligands in the past. Selective agonists are well advanced in clinical trials for the treatment of atrial fibrillation, pain, neuropathy, pulmonary and other inflammatory conditions, and cancer. Selective antagonists have entered clinical trials for the treatment of Parkinson's disease and congestive heart failure. Both in the case of diseases such as stroke, where there is an unmet medical need, and for diseases that already have pharmacological intervention options, the introduction of adenosine-based drug therapy will provide novel mechanisms for therapy. With the maturing of AR science, it is time for some of the myriad of selective agents synthesized to be implemented in the fight to improve human health.
